Table III.
OM 40/AML 5/HCTZ 12.5 mg to OM 40/AML 5/HCTZ 25 mg | OM 40/AML 5/HCTZ 12.5 mg to OM 40/AML 10/HCTZ 12.5 mg | OM 40/AML 5/HCTZ 25 mg to OM 40/AML 10/HCTZ 25 mg | OM 40/AML 10/HCTZ 12.5 mg to OM 40/AML 10/HCTZ 25 mg | |
---|---|---|---|---|
No.a | 604 | 639 | 360 | 383 |
Change in SeDBP, mean (SD) | −2.9 (8.3) | −4.4 (8.7) | −5.7 (9.4) | −5.0 (9.1) |
Change in SeSBP, mean (SD) | −5.9 (13.6) | −6.8 (13.3) | −9.9 (15.0) | −10.2 (13.8) |
Abbreviations: AML, amlodipine besylate; BP, blood pressure; HCTZ, hydrochlorothiazide; OM, olmesartan medoxomil; SD, standard deviation; SeDBP, seated diastolic blood pressure; SeSBP, seated systolic blood pressure. Titration effect was calculated as BP measurement at last visit on the new dose regimen minus BP measurement at last visit of the previous dose regimen. aNumber of titration events. Six participants had duplicate titration events from OM 40/AML 5/HCTZ 12.5 mg to OM 40/AML 10/HCTZ 12.5 mg. Two participants had duplicate titration events from OM 40/AML 10/HCTZ 12.5 mg to OM 40/AML 10/HCTZ 25 mg.